ArticleJournal of viral hepatitis2019
Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.
Article in Journal of viral hepatitis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Explaining the Differences in Opioid Overdose Deaths between Scotland and England/Wales: Implications for European Opioid Policies.European addiction research · 2021Pooled it
- Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care.BMJ (Clinical research ed.) · 2020Trial
- Article
- Estimating the Fraction of Hepatocellular Carcinoma and Decompensated Cirrhosis Attributable to Viral Hepatitis in England Using Electronic Health Records and Case-Notes Review.Journal of viral hepatitis · 2026Article
- Tattoo practices and risk of hepatitis B and hepatitis C infection in the French Constances study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Article
- Estimating Prevalence and Number of People With Chronic Hepatitis B: A Multiplier Method Based on Public Health Surveillance Data in UK (2015-2021).Journal of viral hepatitis · 2025Article
- Pilot postal birth cohort hepatitis C virus screening in UK primary care: HepCAPP study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
- Modelling hepatitis C infection acquired from blood transfusions in the UK between 1970 and 1991 for the Infected Blood Inquiry.Royal Society open science · 2024Article
- Analysis of the UK Government's 10-Year Drugs Strategy-a resource for practitioners and policymakers.Journal of public health (Oxford, England) · 2023Article
- Epidemiology and management of hepatitis B and C in primary care in the Netherlands: data from the Rijnmond Primary Care database.Family practice · 2023Article
- Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination.Journal of viral hepatitis · 2023Article
- Sexually-transmitted hepatitis C virus reinfections among people living with HIV in Taiwan: the emerging role of genotype 6.Emerging microbes & infections · 2022Article
- Cost-effectiveness of chronic hepatitis C screening and treatment.Clinical and molecular hepatology · 2022Review
- Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?Wellcome open research · 2022Article
- Estimating the number of livebirths to Hepatitis C seropositive women in England in 2013 and 2018 using Bayesian modelling.PloS one · 2022Article
- Hepatitis C virus cascade of care in the general population, in people with diabetes, and in substance use disorder patients.Infectious agents and cancer · 2021Article
- Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention.Statistical communications in infectious diseases · 2021Article
- Developing and Piloting a Standardized European Protocol for Hepatitis C Prevalence Surveys in the General Population (2016-2019).Frontiers in public health · 2021Article
- Estimating the prevalence of problem drug use from drug-related mortality data.Addiction (Abingdon, England) · 2020Article
- Increasing uptake of hepatitis C virus infection case-finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial.The British journal of general practice : the journal of the Royal College of General Practitioners · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In England, 160 000 individuals were estimated to be chronically infected with hepatitis C virus (HCV) in 2005 and the burden of severe HCV-related liver disease has increased steadily for the past 15 years. Direct-acting antiviral treatments can clear infection in most patients, motivating HCV elimination targets. However, the current burden of HCV is unknown and new methods are required to monitor progress. We employed a Bayesian back-calculation approach, combining data on severe HCV-related liver disease and disease progression, to reconstruct historical HCV incidence and estimate current prevalence in England. We explicitly modelled infections occurring in people who inject drugs, the key risk group, allowing information on the size of this population and surveillance data on HCV prevalence to inform recent incidence. We estimated that there were 143 000 chronic infections in 2015 (95% credible interval 123 000-161 000), with 34% and 54% in those with recent and past injecting drug use, respectively. Following the planned scale-up of new treatments, chronic infections were predicted to fall to 113 400 (94 900-132 400) by the end of 2018 and to 89 500 (71 300-108 600) by the end of 2020. Numbers developing severe HCV-related liver disease were predicted to fall by at least 24% from 2015 to 2020. Thus, we describe a coherent framework to monitor progress using routinely collected data, which can be extended to incorporate additional data sources. Planned treatment scale-up is likely to achieve 2020 WHO targets for HCV morbidity, but substantial efforts will be required to ensure that HCV testing and patient engagement are sufficiently high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.